KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Retained Earnings (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Retained Earnings for 16 consecutive years, with -$18.1 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 572.5% to -$18.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$18.1 million through Dec 2025, down 572.5% year-over-year, with the annual reading at -$18.1 million for FY2025, 572.5% down from the prior year.
  • Retained Earnings for Q4 2025 was -$18.1 million at Halozyme Therapeutics, down from $502.1 million in the prior quarter.
  • The five-year high for Retained Earnings was $502.1 million in Q3 2025, with the low at -$433.7 million in Q1 2021.
  • Average Retained Earnings over 5 years is $69.6 million, with a median of $0.0 recorded in 2021.
  • The sharpest move saw Retained Earnings tumbled 8304.17% in 2022, then skyrocketed 32306.6% in 2024.
  • Over 5 years, Retained Earnings stood at -$620000.0 in 2021, then surged by 23199.52% to $143.2 million in 2022, then plummeted by 36.77% to $90.6 million in 2023, then crashed by 95.77% to $3.8 million in 2024, then tumbled by 572.5% to -$18.1 million in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$18.1 million, $502.1 million, and $361.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.